交银国际：首次覆盖劲方医药-B(02595)给予买入评级 目标价51港元

Core Viewpoint - The report by CMB International initiates coverage of Jinfang Pharmaceutical-B (02595) with a "Buy" rating and a target price of HKD 51, highlighting the company's innovative drug pipeline and strong management team [1] Group 1: Product Pipeline and Innovation - The company has established a diversified product pipeline focused on challenging RAS targets, leveraging deep understanding and successful development experience to create a candidate matrix that includes KRASG12C/G12D and pan-RAS, among others [1] - GFH925 (Fuzeracib) has been approved for marketing in mainland China, marking it as the first domestic product targeting the same RAS family member [1] - The product pipeline also extends to other significant indications such as tumors, cachexia, autoimmune, and inflammatory diseases, targeting promising areas like RIPK1 and GDF15/IL-6 [1] Group 2: Clinical Data and Competitive Advantage - The company demonstrates a competitive edge in RAS-targeted drug development, with GFH925 showing excellent efficacy in 2L+ KRASG12C mutation non-small cell lung cancer (NSCLC) patients, outperforming overseas competitors [2] - GFH375 is among the first globally to enter Phase III clinical trials for KRASG12D, showing promising initial data compared to major competitors [2] - The dual antibody GFS202A targeting GDF15/IL-16 is progressing rapidly, with early signs of tolerability and activity advantages over single-target drugs [2] Group 3: Management and Strategic Partnerships - The company has assembled a core management team with an average of over 20 years of industry experience, achieving a record of six years from project initiation to market launch for GFH925 [3] - The company actively seeks diverse global development opportunities and strategically selects partners to create value through complementary strengths, collaborating with notable firms such as Innovent Biologics, Merck, and Verastem [3] Group 4: Financial Projections and Valuation - The company is projected to achieve revenues of RMB 1.09 billion, 0.85 billion, and 1.18 billion in 2025-2027, primarily driven by sales of GFH925 in mainland China and overseas collaboration income from GFH375 [4] - Using a DCF valuation model, the target price of HKD 51 corresponds to a 2.3x peak revenue sales multiple and an 87% potential upside [4] - Future focus will be on the sales ramp-up of GFH925 post-inclusion in medical insurance and additional data readouts from the RAS pipeline [4]